Supplementary materials

Table1. Values obtained for the intact control animals (Figure 2, A).

Value	Intact control animals	3-day administration of cyclophosphamide *
Red blood cells count	$(6.5\pm1.4)\cdot10^{12}$/L	$(4.93 \pm 1.3)\cdot10^{12}$ /L
Hemoglobin	(140.7 ± 1.2) g/L	(90.75 ± 12.0) g /L
Hematocrit	(39.8 ± 1.9) %	(21.21 ± 2.58) %
Platelet count	$(650.6\pm36.0)\cdot10^{9}$/ L	$(70.5 \pm 4.3)\cdot10^{9}$/L
Trombocrit	(12.6 ± 0.3) %	
White blood cell count	$(10.18\pm1.11)\cdot10^{9}$/L	$(1.91 \div 2.44)\cdot10^{9}$/L
Lymphocytes cells	$(5.18\pm1.1)\cdot10^{9}$/L with a percentage of 50.9 ± 0.9 %	$(21.1 \div 29.13)$ %
Granulocytic leucocytes cells	$(4.49\pm0.9)\cdot10^{9}$/L with a percentage of (44.1 ± 0.4) %	
Monocytes count	$(0.52\pm0.01)\cdot10^{9}$/L with a percentage of 5.1 ± 0.7 %	28.4 ± 1.01 %
* Red blood cell count dropped in 1.32 times; Hemoglobin level dropped in 1.6 times; Hematocrit value dropped in1.88 times; Platelet cells count dropped in 9.22 times.		

Table 2. Total leukocyte count ($\cdot10^{9}$ /L of blood) of hemogram of animals after administration of the compounds **3, 8-11**

Compound	Day of administration of 3, 8-11			
	1st	7th	21st	28th
3	2.1±0.01	2.2±0.01	4.3±0.01	6.9±0.3
8	2.3±0.01	3.2±0.02	6.5±0.01	6.8±0.2
9	1.9±0.00	2.6±0.02	4.7±0.02	8.7±0.2
10	1.9±0.01	2.2±0.01	4.2±0.1	6.2±0.1
11	2.1±0.01	2.8±0.01	4.6±0.02	8.2±0.6
Intact group	10.2±0.5	10.2±0.9	10.1±0.05	10.1±0.8
Control group	1.9±0.01	2.3±0.01	2.3±0.01	5.5±0.2
Methyluracil*	2.3±0.2	3.2±0.01	4.1±0.01	6.2±0.3

*reference drug

Table 3. The relative granulocyte index (%) of the blood hemogram of animals after administration of the compounds **3, 8-11**

Compound	Day of administration of 3, 8-11			
	1st	7th	21st	28th
3	49.2±1.1	44.4±1.2	46.4±1.6	51.7±1.2
8	48.4±1.2	32.2±1.5	54.9±1.5	54.9±1.3
9	48.4±1.4	38.6±1.2	48.1±1.2	48.5±1.2
10	44.1±1.1	37.2±1.1	46.1±1.1	47.5±1.1
11	49.6±0.9	37.2±1.5	49.6±1.2	46.2±1.3
Intact group	44.4±1.3	44.4±1.1	46.1±1.2	42.4±1.2
Control group	50.1±1.9	40.1±1.1	42.0±1.1	34.4±1.1
Methyluracil*	52.1±1.9	44±1.2	44.4±1.2	49.8±1.3

*reference drug

Table 4. The relative monocytic-eosinophilic index (%) of blood hemogram of animals after administration of the compounds **3, 8-11**

Compound	Day of administration of 3, 8-11			
	1st	7th	21st	28th
3	27.4±1.2	29.2±1.5	12.4±0.8	7.9±0.5
8	22.5±1.4	36.6±1.8	17.2±0.8	8.5±0.9
9	28.4±1.5	39±1.5	13.7±0.9	8.4±0.4
10	22.4±1.2	33.2±1.1	11.1±0.9	8.2±0.1
11	22.0±1.8	33.2±1.8	10.0±0.9	9.4±0.9
Intact group	5.1±0.02	4.4±0.01	1.8±0.8	3.2±0.02
Control group	28.8±1.4	49.5±1.2	45.6±2.4	32.5±1.1
Methyluracil*	20.8±1.2	25.9±1.2	21.2±1.1	13.4±0.9

*reference drug

Table 5. The relative lymphocyte index (%) of the blood hemogram of animals after administration of the compounds **3, 8-11**

Compound	Day of administration of 3, 8-11			
	1st	7th	21st	28th
3	23.4±1.0	28.4±1.2	41.2±1.4	40.4±0.9
8	29.1±1.3	31.2±0.8	35.1±1.4	36.6±0.9
9	23.2±0.9	22.4±1.1	38.2±1.3	43.1±0.8
10	23.5±1.1	22.8±1.0	35.2±1.0	41.2±1.1
11	28.4±1.2	39.6±0.8	40.4±0.9	44.4±0.1
Intact group	50.9±1.0	50.2±0.9	52.1±1.3	54.4±0.8
Control group	21.1±1.3	10.4±1.4	12.4±1.2	33.1±1.4
Methyluracil*	27.1±1.0	30.1±1.1	34.4±1.0	36.8±0.5

*reference drug

Table 6. The monocyte index ($\cdot 10^6/\mu L$) of bone marrow myelogram of animals after administration of compounds **3**, **9**, **11**

Compound	Day of administration of 3, 9, 11						
	2	4(1)	6(3)	8(5)	10(7)	14(11)	21(18)
3	0.3±0.00	0.5±0.01	1.6±0.02	1.2±0.01	2.2±0.02	2±0.00	4±0.02
9	0.2±0.01	0.5±0.01	1.4±0.01	1.1±0.01	1.8±0.01	2.2±0.01	4.6±0.02
11	0.2±0.01	0.6±0.01	1.9±0.01	1.2±0.01	3.1±0.00	2.2±0.01	5.1±0.02
Methyluracil*	0.2±0.01	0.4±0.01	0.8±0.01	0.9±0.01	0.9±0.01	1.8±0.00	2±0.01
Control group	0.3±0.01	0.5±0.01	0.8±0.02	0.5±0.01	0.4±0.02	0.8±0.01	1.5±0.01
Placebo (saline solution)	0.2±0.00	0.4±0.01	0.7±0.01	0.4±0.01	0.8±0.02	1.2±0.01	1.5±0.00
Intact group	3.9±0.03	3.9±0.00	4±0.01	4.2±0.01	3.8±0.01	4.2±0.01	3.8±0.00

*reference drug

Table 7. Myelokaryocytic index ($\cdot 10^6/\mu L$) of bone marrow myelogram of animals after administration of compounds **3**, **9**, **11**

Compound	Day of administration of 3, 9, 11						
	2	4(1)	6(3)	8(5)	10(7)	14(11)	21(18)
3	5.2±0.02	8.1±0.7	12.2±1.2	14.1±1.2	16.2±1.1	18.4±1.2	14.1±1.5
9	4.9±0.01	8.8±0.8	11.8±0.9	13.9±1.1	18.2±1.2	19.1±1.4	15±0.9
11	4.9±0.01	8.9±0.8	13.4±1.0	16.7±1.3	19.1±1.1	22.4±2.1	18.2±1.3
Methyluracil*	4.8±0.01	8.4±0.8	10.2±0.9	8.9±0.9	8.4±1.2	6.8±0.9	10.4±0.8

Control group	5.2±0.5	5.4±0.4	12.2±0.8	11.8±1.1	10.4±0.9	10.5±1.9	15.2±1.2
Placebo (saline solution)	5.1±0.6	5.2±0.5	10.2±0.9	10±0.9	8.2±0.9	10.2±1.2	13±1.1
Intact group	18.2±0.9	18.4±1.2	18±1.2	17.9±2.1	18±1.2	17.8±1.2	17.9±0.9

*reference drug

Table 8. The granulocyte index ($\cdot 10^6/\mu L$) of bone marrow myelogram of animals after administration of the compounds **3, 9, 11**

Compound	Day of administration of 3, 9, 11						
	2	**4(1)**	**6(3)**	**8(5)**	**10(7)**	**14(11)**	**21(18)**
3	2.9±0.01	4.5±0.01	5.2±0.01	14.2±0.8	13.4±0.8	14.4±1.0	9.8±0.9
9	2.9±0.01	4.3±0.01	9.1±0.01	12.8±0.9	13.1±0.9	16.2±1.1	11.2±0.9
11	2.6±0.00	4.8±0.00	12.1±0.08	18.3±0.9	21.3±0.8	20.4±1.1	14.6±1.1
Methyluracil*	2.7±0.01	8±0.01	4.9±0.00	10.4±0.5	8.4±0.5	9.4±0.9	10.1±0.9
Control group	2.9±0.00	3.2±0.01	5.1±0.01	10.1±0.6	8.4±0.6	7.9±0.9	8.2±0.9
Placebo (saline solution)	2.8±0.01	3±0.01	5.1±0.02	4.5±0.2	8.4±0.4	7.9±0.9	9.9±0.9
Intact group	7.9±0.01	8.2±0.03	7.9±0.8	8±0.5	8.2±0.4	8.2±0.9	8.3±0.9

*reference drug

Table 9. The total erythrocyte index ($\cdot 10^6/\mu L$) of bone marrow myelogram of animals after administration of the compounds **3, 9, 11**

Compound	Day of administration of 3, 9, 11						
	2	**4(1)**	**6(3)**	**8(5)**	**10(7)**	**14(11)**	**21(18)**
3	1.3±0.02	1.8±0.01	2.2±0.0	2.8±0.01	2.5±0.01	4±0.01	4.2±0.01
9	1.4±0.01	2±0.02	2.3±0.0	2.8±0.2	2.8±0.01	4.2±0.01	4.5±0.01
11	1.5±0.01	2±0.00	2.3±0.0	2.9±0.01	2.5±0.05	4.3±0.01	4.5±0.01
Methyluracil*	1.4±0.00	1.9±0.1	2.4±0.02	2.5±0.2	2.9±0.2	4.1±0.02	3.9±0.01
Control group	1.2±0.01	1.8±0.1	2.1±0.00	2.4±0.05	2.5±0.2	4.2±0.02	4.3±0.00
Placebo (saline solution)	1.3±0.01	1.5±0.09	2±0.0	2.9±0.06	3±0.05	4.5±0.02	4.6±0.01
Intact group	4.8±0.3	4.9±0.08	5±0.8	4.7±0.05	5.2±0.05	4.6±0.02	5±0.6

*reference drug